AGRP has been shown to stimulate appetite, diminish energy expenditure, and contribute to obesity, while also elevating the risk of adverse cardiovascular outcomes in the context of AMI (Liu et al., 2023). Here, AGRP is linked to obesity due to melanocortin 4 receptor deficiency.